Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$24.02 USD
+0.94 (4.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $24.04 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Earnings News For NRIX
-
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
-
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
-
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
-
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
-
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates
-
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
-
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
-
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
-
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
-
Nurix (NRIX) to Report Q3 Earnings: What's in Store?
-
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates
-
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
-
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
-
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
-
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
-
Will Nurix Therapeutics, Inc. (NRIX) Report Negative Q1 Earnings? What You Should Know
-
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
-
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update
-
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
-
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update
-
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates
-
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
-
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
-
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Tops Revenue Estimates